Agile Therapeutics (AGRX) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Agile Therapeutics (AGRXResearch Report) yesterday and set a price target of $3.00. The company’s shares closed last Monday at $1.13.

According to, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -26.7% and a 20.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Hancock Jaffe Laboratories Inc, and Aridis Pharmaceuticals Inc.

Agile Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $3.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.70 and a one-year low of $0.53. Currently, Agile Therapeutics has an average volume of 718.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.